Virios Therapeutics, Inc. (VIRI): Price and Financial Metrics


Virios Therapeutics, Inc. (VIRI): $0.31

-0.01 (-3.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VIRI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VIRI Stock Price Chart Interactive Chart >

Price chart for VIRI

VIRI Price/Volume Stats

Current price $0.31 52-week high $9.11
Prev. close $0.32 52-week low $0.22
Day low $0.29 Volume 306,205
Day high $0.32 Avg. volume 443,895
50-day MA $0.28 Dividend yield N/A
200-day MA $3.01 Market Cap 2.57M

Virios Therapeutics, Inc. (VIRI) Company Bio


Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.


VIRI Latest News Stream


Event/Time News Detail
Loading, please wait...

VIRI Latest Social Stream


Loading social stream, please wait...

View Full VIRI Social Stream

Latest VIRI News From Around the Web

Below are the latest news stories about VIRIOS THERAPEUTICS INC that investors may wish to consider to help them evaluate VIRI as an investment opportunity.

Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022

The Planet MicroCap Showcase: VIRTUAL taking place on December 6-8, 2022, where 49 MicroCap public companies will be presenting virtually.

Yahoo | December 5, 2022

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

ATLANTA, November 29, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022.

Yahoo | November 29, 2022

VIRI: Ready to Approach FDA with Phase 3 Plans…

By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Business Update Post-Hoc Analysis of Phase 2b FORTRESS Trial Shows Naïve Patients Responded to IMC-1 Treatment In September, 2022, Virios Therapeutics, Inc. (NASDAQ:VIRI) announced topline results for the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1) trial of

Yahoo | November 22, 2022

H.C. Wainwright Remains a Hold on Virios Therapeutics (VIRI)

H.C. Wainwright analyst Sean Lee CFA maintained a Hold rating on Virios Therapeutics (VIRI - Research Report) today. The company's shares closed yesterday at $0.32.According to TipRanks, Lee CFA is an analyst with an average return of -18.8% and a 26.36% success rate. Lee CFA covers the Healthcare sector, focusing on stocks such as Gritstone Oncology, Plus Therapeutics, and CASI Pharmaceuticals.The word on The Street in general, suggests a Hold analyst consensus rating for Virios Therapeutics.See the top stocks recommended by analysts >>Based on Virios Therapeutics' latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.67 million.

Carrie Williams on TipRanks | November 15, 2022

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

ATLANTA, November 14, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia ("FM"), today announced financial results for the third quarter ended September 30, 2022, as well as plans to advance development of its lead antiviral development candidate, IMC-1, as a potential new treatment for FM patients.

Yahoo | November 14, 2022

Read More 'VIRI' Stories Here

VIRI Price Returns

1-mo 31.36%
3-mo 3.51%
6-mo -95.57%
1-year -95.16%
3-year N/A
5-year N/A
YTD 31.36%
2022 -95.39%
2021 -31.89%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6887 seconds.